Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (41-50 of 252) with videos related to

Pageof 26
Sort By:
The Cochrane Database of Systematic Reviews|October 19, 2012
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesFrauke Naumann-Winter, Alexander Greb, Peter Borchmann, et al.
Oncology and Therapy|November 29, 2022
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data AnalysisPeter Borchmann, Jan-Michel Heger, Jörg Mahlich, et al.
Critical Reviews in Oncology/Hematology|March 14, 2016
PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysisMarie T Sickinger, Bastian von Tresckow, Carsten Kobe, et al.
The Cochrane Database of Systematic Reviews|January 10, 2015
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphomaMarie-Therese Sickinger, Bastian von Tresckow, Carsten Kobe, et al.
The Lancet. Oncology|August 17, 2013
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysisNicole Skoetz, Sven Trelle, Michaela Rancea, et al.
Frontiers in Oncology|October 24, 2024
Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019Jan-Michel Heger, Peter Borchmann, Sybille Riou, et al.
Haematologica|May 10, 2007
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)Sven Trelle, Orhan Sezer, Ralph Naumann, et al.
Journal of Cancer Research and Clinical Oncology|March 4, 2023
Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims databasePeter Borchmann, Jan-Michel Heger, Jörg Mahlich, et al.
Future Oncology (London, England)|May 13, 2026
Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carersJustin Ferdinandus, Maximilian Buettner, John Stavliotis, et al.
Haematologica|July 17, 2025
Long non-coding RNA LINC00926 is a biomarker for naïve B-cells with prognostic value in advanced stage classic Hodgkin LymphomaIngram Iaccarino, Thomas Beder, Sarah Reinke, et al.
Pageof 26

Showing results (41-50 of 252) with videos related to

Sort By:
Pageof 26
The Cochrane Database of Systematic Reviews|October 19, 2012
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesFrauke Naumann-Winter, Alexander Greb, Peter Borchmann, et al.
Oncology and Therapy|November 29, 2022
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data AnalysisPeter Borchmann, Jan-Michel Heger, Jörg Mahlich, et al.
Critical Reviews in Oncology/Hematology|March 14, 2016
PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysisMarie T Sickinger, Bastian von Tresckow, Carsten Kobe, et al.
The Cochrane Database of Systematic Reviews|January 10, 2015
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphomaMarie-Therese Sickinger, Bastian von Tresckow, Carsten Kobe, et al.
The Lancet. Oncology|August 17, 2013
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysisNicole Skoetz, Sven Trelle, Michaela Rancea, et al.
Frontiers in Oncology|October 24, 2024
Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019Jan-Michel Heger, Peter Borchmann, Sybille Riou, et al.
Haematologica|May 10, 2007
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)Sven Trelle, Orhan Sezer, Ralph Naumann, et al.
Journal of Cancer Research and Clinical Oncology|March 4, 2023
Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims databasePeter Borchmann, Jan-Michel Heger, Jörg Mahlich, et al.
Future Oncology (London, England)|May 13, 2026
Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carersJustin Ferdinandus, Maximilian Buettner, John Stavliotis, et al.
Haematologica|July 17, 2025
Long non-coding RNA LINC00926 is a biomarker for naïve B-cells with prognostic value in advanced stage classic Hodgkin LymphomaIngram Iaccarino, Thomas Beder, Sarah Reinke, et al.
Pageof 26